期刊文献+

放射治疗转移性肝癌的临床预后因素研究 被引量:1

The research for clinical prognotic factors of metastatic liver cancer treated with radiotherapy
下载PDF
导出
摘要 目的:分析转移性肝癌应用放疗的疗效及预后因子。方法:转移性肝癌患者38例,21例经肝动脉栓塞化疗药物灌注(TACE)2~3次后行外放疗,17例进行单纯放射治疗,38例患者总照射剂量TD2000Gy^6600CGy,分割剂量150Gy^200CGy/次,每周5次。结果:所有患者均完成治疗过程,总有效率(PR+CR)为86.8%,1年及2年生存率为55.3%,36.8%。应用SAS6.0软件单因素分析显示肝内转移数量、经动脉栓塞化疗(TACE)、适形放疗、Child-Pugh分级是对预后的影响有统计学意义的因素(P<0.001),COX回归分析上述因素也是独立的预后因子(P<0.05)。结论:经动脉栓塞化疗(TACE)、适形放疗、肝内转移数量和Child-Pugh分级对转移性肝癌放疗的生存率有显著影响,同时也是独立的预后因子。 Objective:To evaluate the efficacy of liver metastases cancer treated by radiotherapy, and investigate the prognostic factors. Methods : From August 1997 to November 2003, 38 patients who have been diagnozed liver metastases cancer received radiotherapy,21 patients received transarterial chemoembolization ( TACE ) 2 - 4 weeks before radiotherapy, and 17 patients treated by radiotherapy alone. Radiotherapy include normal radiotherapy and 3 - dimensional conformal radiation therapy (3 - DCRT). The total irradiation dose was 20Gy to 65 Gy in daily fraction of 150Gy -200CGy. Results: All patients could tolerate the side effect. The response rate (CR + PR) was 86.8% , 1 -year and 2 -year survival rates were 55.3% ,36.8%. The number of metastases, TACE, 3 - DCRT, Child - Pugh Grade had significant role on the 1 - year overall survival ( P 〈 0.001 ). The number of metastases, Child - Pugh Grade, TACE and 3 - DCRT were independent significant prognostic factors ( P 〈 0. 05 ). Conclusion. The number of metastases, TACE, 3 - DCRT, Child - Pugh Grade have significant role on the overall survival in liver metastases cancer patients received radiotherapy, and these factors also are independent prognostic factors.
出处 《现代肿瘤医学》 CAS 2006年第12期1590-1592,共3页 Journal of Modern Oncology
关键词 转移性肝癌 经动脉栓塞化疗 放疗 预后 liver metastases cancer TACE radiotherapy prognosis
  • 相关文献

参考文献6

  • 1金冶宁,王雅杰,孟岩,肖作平,张晓青,张可领.356例肝癌的放疗和综合治疗[J].中华放射肿瘤学杂志,1997,6(3):157-161. 被引量:20
  • 2Zeng ZC,Tang ZY,Wu ZQ,et al.Phase Ⅰ clinical trial of oral Furtulon and combined hepatic arterial chemoembolization and radiotherapy in unresectable primary liver cancers,including clinicopathologic study[J].Am J Clin Oncol (CCT),2000,23:449~454.
  • 3Greco C,Catalano G,Di Grazia A,et al.Radiotherapy of liver malignancies.From whole liver irradiation to stereotactic hypofractionated[J].Radiotherapy,2004,90(1):73~79.
  • 4梁世雄,蒋国梁,朱小东,傅小龙,陆海杰,潘朝阳,黄启芳,黎福祥,王安宇.原发性肝癌三维适形放疗后放射性肝病的影响因素[J].中华放射肿瘤学杂志,2005,14(4):284-288. 被引量:42
  • 5Schefter TE,Kavanagh BD,Timmerman RD,et al.A phase Ⅰ trial of stereotactic body radiation therapy (SBRT) for liver metastases[J].Int J Radiat Oncol Biol Phys,2005,62(5):1371~1378.
  • 6Ben -Josef E,Normolle D,Ensminger WD,et al.Phase Ⅱ trial of high-dose conformal radiation therapy with concurrent hepatic artery floxuridine for unresectable intrahepatic malignancies[J].J Clin Oncol,2005,23 (34):8739~8747.

二级参考文献10

  • 1Lawrence TS, Ten-Haken RK, Kessler ML, et al. The use of 3-D dose volume analysis to predict radiation hepatitis. Int J Radiat Oncol Biol Phys,1992,23:781-788.
  • 2Dawson LA, Ten-Haken RK, Lawrence TS.Partial irradiation of the liver.Semin Radiat Oncol,2001,11:240-246.
  • 3Trotti A,Byhardt R,Stetz J,et al.Common Toxicity Criteria: version2.0.An improved reference for grading the acute effects of cancer treatment:impact on radiotherapy. Int J Radiat Oncol Biol Phys,2000,47:13-47.
  • 4Lawrence TS, Dworznin LM, Walker-Andrews SC, et al. Treatment of cancers involving the liver and portal hepatic with external irradiation and intra arterial hepatic fluorodeoxyuridine. Int J Radiat Oncol Biol Phys,1991,20:551-651.
  • 5Robertson JM, Lawrene TS, Wolker S, et al. The treatment of colorectal liver metastases with conformal radiation therapy and regional chemotherapy. Int J Radiat Oncol Biol Phys, 1995,32:445-450.
  • 6Ohara K, Okumura T, Tsuji H, et al. Radiation tolerance of cirrhotic livers in relation to the preserved functional capacity: analysis of patients with hepatocellular carcinoma treated by focused proton beam radiotherapy. Int J Radiat Oncol Biol Phys, 1997,38:367-372.
  • 7McGinn CJ, Ten-Haken RK,Ensminger WD,et al. Treatment of intrahepatic cancers with radiation doses based on a normal tissue complication probability model. J Clin Oncol, 1998,16: 2246-2252.
  • 8Ten-Haken RK,Balter JM, Marsh LH, et al. Potential benefits of eliminating planning target volume expansions for patient breathing in the treatment of liver tumors. Int J Radiat Oncol Biol Phys, 1997,38:613-617.
  • 9Dawson LA, Normolle D, Balter J, et al. Analysis of radiation induced liver disease using the lyman NTCP model. Int J Radiat Oncol Biol Phys,2002, 53: 810-821.
  • 10Cheng JC, Wu JK, Huang CM, et al. Radiation-induced liver disease after three-dimensional conformal radiotherapy for patients with hepatocellular carcinoma:dosimetric analysis and implication. Int J Radiat Oncol Biol Phys,2002,54:156-162.

共引文献60

同被引文献5

  • 1Feng M,Ben-Josef E. Radiation therapy for hepatocellular carcinoma [J] .Semin Radiat Oncol, 2011,21 (4):271-277.
  • 2Hoffe SE,Finkelstein SE,Russell MS,et al. Nonsurgical options for hepatocellular carcinoma: evolving role of ex- ternal beam radiotherapy [J]. Cancer Control,2010,17(2): 100-110.
  • 3Dawson LA,Ten Haken RK.Partial volume tolerance of the liver to radiation [J].Semin Radiat Oncol,2005,15(4): 279-283.
  • 4黎功.肝癌放疗研究进展[J].肿瘤学杂志,2010,16(7):516-519. 被引量:10
  • 5梁世雄,蒋国梁,周振华,杨焕军,张小建,林钧华.肝癌介入治疗和三维适形放疗的临床Ⅰ/Ⅱ期试验[J].中国癌症杂志,2004,14(1):48-51. 被引量:20

引证文献1

二级引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部